CD27

CD27 詳細

英語名CD27 antigen市販薬剤の数0
治験薬の数4ターゲットの別称CD27 antigen,Tumor necrosis factor receptor superfamily member 7,CD27L receptor,CD27,CD27 Molecule,T-Cell Activation Antigen CD27,TNFRSF7,T14,T Cell Activation Antigen S152,S152. LPFS2,S152,Tp55,Tumor Necrosis Factor Receptor Superfamily, Member 7
研究&開発段階Phase 2 Clinical
英語名CD27 antigen
ターゲットの別称CD27 antigen,Tumor necrosis factor receptor superfamily member 7,CD27L receptor,CD27,CD27 Molecule,T-Cell Activation Antigen CD27,TNFRSF7,T14,T Cell Activation Antigen S152,S152. LPFS2,S152,Tp55,Tumor Necrosis Factor Receptor Superfamily, Member 7
市販薬剤の数0
治験薬の数4
研究&開発段階Phase 2 Clinical

CD27 製品リスト

  • 属性

    Protein (6)

  • 製品ライブラリ

    オンライン (6)

  • Human (4)Cynomolgus / Rhesus macaque (1)Mouse (1)

  • タグ

    Fc Tag (1)Fc Tag & Avi Tag (1)Mouse IgG Fc Tag (3)His Tag (1)

  • マーカー

    Unconjugated (5)Biotin-labeled (1)

CD27バックグランド

CD Antigen CD27 is also known as Tumor necrosis factor receptor superfamily member 7 (TNFRSF7), which belongs to TNF-receptor superfamily. CD27 / TNFRSF7 is found in most T-lymphocytes. CD27 / TNFRSF7 is required for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. This receptor transduces signals that lead to the activation of NF-κB and MAPK8/JNK. CD27 has been shown to interact with SIVA1, TRAF2 and TRAF3.

CD27分子の別称

CD27,TNFRSF7,S152,T14,Tp55

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
VarlilumabCDX-1127Phase 2 ClinicalCelldex TherapeuticsAdenocarcinoma; Astrocytoma; Bile Duct Neoplasms; Burkitt Lymphoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Central Nervous System Lymphoma; Cholangiocarcinoma; Gallbladder Neoplasms; Glioblastoma; Glioma; Head and Neck Neoplasms; Hormone-Resistant Prostate Neoplasms; Kidney Diseases; Kidney Neoplasms; Large intestine neoplasm; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Lung Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, Primary Effusion; Lymphoma, T-Cell; Lymphomatoid Granulomatosis; Melanoma; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Plasmablastic Lymphoma; Prostatic Neoplasms; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms; Urologic Diseases; Urologic Neoplasms
詳細
BoserolimabMK-5890Phase 1 ClinicalBioNovion Holding BVBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Solid tumours; Triple Negative Breast Neoplasms
詳細
LOR-S03CDX-527Phase 1 ClinicalCelldex TherapeuticsBreast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms
詳細
Anti-CD27 monoclonal antibody (Aduro Biotech)BION-1402Phase 1 ClinicalAduro Biotech IncNeoplasms
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8